Trial
NCT01289210
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
Stanford University
Condition
Low Grade B Cell Lymphoma
Intervention
VTX-2337 plus radiotherapy
Why stopped
The study was stopped due to slow rate of recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-25